Intratumoral Combinatorial Administration of CD1c (BDCA-1)(+) Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in re-licensing antitumor cytotoxic T lymphocytes. IT injection of the IgG(1) monoclonal antibodies ipilimumab and avelumab may induce antibody-dependent cellular cytotoxicity, thereby enhancing the release of tumor antigens that...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarze, Julia Katharina, Awada, Gil, Cras, Louise, Tijtgat, Jens, Forsyth, Ramses, Dufait, Inès, Tuyaerts, Sandra, Van Riet, Ivan, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712037/
https://www.ncbi.nlm.nih.gov/pubmed/33182610
http://dx.doi.org/10.3390/vaccines8040670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712037/
https://www.ncbi.nlm.nih.gov/pubmed/33182610
http://dx.doi.org/10.3390/vaccines8040670

Ejemplares similares